Home Tools
Log in
Cart

Nintedanib

Catalog No. T1777   CAS 656247-17-5
Synonyms: BIBF 1120, Intedanib

Nintedanib (Intedanib) is a triple vascular kinase inhibitor that inhibits VEGFR1, VEGFR2, and VEGFR3 (IC50=34/13/13 nM), FGFR1, FGFR2, and FGFR3 (IC50=69/37/108 nM), PDGFRα, and PDGFRβ (IC50=59/65 nM). Nintedanib has antitumor activity and inhibits tumor growth by inhibiting angiogenesis.

All products from TargetMol are for Research Use Only. Not for Human or Veterinary or Therapeutic Use.
Nintedanib Chemical Structure
Nintedanib, CAS 656247-17-5
Pack Size Availability Price/USD Quantity
5 mg In stock $ 38.00
10 mg In stock $ 54.00
50 mg In stock $ 64.00
100 mg In stock $ 93.00
200 mg In stock $ 144.00
1 mL * 10 mM (in DMSO) In stock $ 50.00
Bulk Inquiry
Get quote
Select Batch  
Purity: 99.92%
Purity: 99.72%
Purity: 99.65%
Purity: 99.36%
Purity: 98%
Contact us for more batch information
Biological Description
Chemical Properties
Storage & Solubility Information
Description Nintedanib (Intedanib) is a triple vascular kinase inhibitor that inhibits VEGFR1, VEGFR2, and VEGFR3 (IC50=34/13/13 nM), FGFR1, FGFR2, and FGFR3 (IC50=69/37/108 nM), PDGFRα, and PDGFRβ (IC50=59/65 nM). Nintedanib has antitumor activity and inhibits tumor growth by inhibiting angiogenesis.
Targets&IC50 PDGFRα:59 nM (cell free), FGFR1:69 nM (cell free), FGFR2:37 nM (cell free), VEGFR1:34 nM (cell free), VEGFR3:13 nM (cell free), VEGFR2:13 nM (cell free)
In vitro METHODS: Human nasopharyngeal carcinoma cells CNE-2, HNE-1 and HONE-1 were treated with Nintedanib (0.078-10 µM) for 72 h, and cell viability was measured by CCK8 assay.
RESULTS: Nintedanib significantly inhibited the growth of CNE-2, HNE-1 and HONE-1 cell lines in a dose-dependent manner with IC50 values of 4.16 µM, 5.62 µM and 6.32 µM, respectively. [1]
METHODS: Human endothelial cells HUVEC, smooth muscle cells HUASMC and bovine pericytes were treated with Nintedanib (0.03-1 µM) for 2 h, and the expression levels of target proteins were detected by Western Blot.
RESULTS: Nintedanib inhibited ligand-dependent phosphorylation of MAPK and Akt in HUVEC, HUASMC and bovine pericytes. [2]
In vivo METHODS: To test the antitumor activity in vivo, Nintedanib (10-100 mg/kg) was administered by gavage to athymic NMRI-nu/nu mice bearing the human head and neck small cell carcinoma tumor FaDu or the human renal carcinoma tumor Caki-1 once daily for 23-35 days.
RESULTS: Nintedanib inhibited tumor growth in FaDu and Caki-1. [2]
METHODS: To test the antitumor activity in vivo, Nintedanib (40 mg/kg) and TFTD (150 mg/kg) were administered intraperitoneally to BALB/c nu/nu mice bearing tumors of DLD-1, DLD-1/5-FU, HT-29, or HCT116 twice daily for two weeks.
RESULTS: At day 15, Nintedanib and TFTD monotherapy resulted in a significant reduction in tumor growth in vivo. The combination therapy exhibited greater anti-tumor activity than the two monotherapies. [3]
Kinase Assay The cytoplasmic tyrosine kinase domain of VEGFR-2 (residues 797–1355 according to sequence deposited in databank SWISS-PROT P35968) was cloned into pFastBac fused to GST and extracted as described in supplementary methods. Enzyme activity was assayed using standard conditions using a random polymer (Glu/Tyr 4:1) and in the presence of 100 μmol/L ATP (for details, see supplementary methods). For all other kinase assays, the entire cytoplasmic domains of the receptors (from the end of the transmembrane to the COOH terminus) were cloned into pFastBac vector containing GST and assayed under standard conditions [1].
Cell Research HUVEC, HUASMC, and BRP were cultured as described above. Two hours before the addition of ligands, BIBF 1120 was added to the cultures. Cell lysates were generated according to standard protocols. Western blotting was done using standard SDS-PAGE methods, loading 50 to 75 μg of protein per lane, with detection by enhanced chemiluminescence. Total and phosphorylated mitogen-activated protein kinase (MAPK) was analyzed using monoclonal antibodies M3807 and M8159. Total Akt was detected using the polyclonal antibody and phosphorylated Akt (Ser473) was analyzed with the monoclonal antibody. Cleaved caspase-3 was detected with the monoclonal antibody [1].
Animal Research Five-week-old to 6-wk-old athymic NMRI-nu/nu female mice (21–31 g) were purchased from Harlan. After acclimatization, mice were inoculated with 1 to 5 × 10^6 (in 100 μL) FaDu, Caki-1, SKOV-3, H460, HT-29, or PAC-120 cells s.c. into the right flank of the animal. F344 Fischer rats after acclimatization were injected with 5 × 10^6 (in 100 μL) GS-9L cells s.c. into the right flank of the animal. For pharmacokinetic analysis, blood was isolated at indicated time points from the retroorbital plexus of mice and plasma was analyzed using high-performance liquid chromatography-mass spectrometry methodology [1].
Synonyms BIBF 1120, Intedanib
Molecular Weight 539.62
Formula C31H33N5O4
CAS No. 656247-17-5

Storage

keep away from direct sunlight

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Solubility Information

Ethanol: 3 mg/mL (5.55 mM)

DMSO: 6 mg/mL (11.11 mM)

H2O: < 1 mg/mL (insoluble or slightly soluble)

TargetMolReferences and Literature

1. Xue C, et al. Efficacy of BIBF 1120 or BIBF 1120 plus chemotherapy on nasopharyngeal carcinoma in vitro and in vivo. Drug Des Devel Ther. 2016 Mar 15;10:1173-80. 2. Hilberg F, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008 Jun 15;68(12):4774-82. 3. Suzuki N, et al. Effect of a novel oral chemotherapeutic agent containing a combination of trifluridine, tipiracil and the novel triple angiokinase inhibitor nintedanib, on human colorectal cancer xenografts. Oncol Rep. 2016 Dec;36(6):3123-3130.

TargetMolCitations

1. Dong X, Wang L, Wang D, et al.Proteomic study on nintedanib in gastric cancer cells.PeerJ.2024, 12: e16771.

Related compound libraries

This product is contained In the following compound libraries:
Anti-Cancer Drug Library Kinase Inhibitor Library Anti-Cancer Active Compound Library Membrane Protein-targeted Compound Library Anti-Cancer Approved Drug Library Tyrosine Kinase Inhibitor Library Drug Repurposing Compound Library EMA Approved Drug Library Inhibitor Library Anti-Cancer Clinical Compound Library

Related Products

Related compounds with same targets
N-Desethylsunitinib hydrochloride SU11274 Riddelline (Z)-Guggulsterone JK-P3 RAF265 SU5205 TAK-593

TargetMolDose Conversion

You can also refer to dose conversion for different animals. More

TargetMol In vivo Formulation Calculator (Clear solution)

Step One: Enter information below
Dosage
mg/kg
Average weight of animals
g
Dosing volume per animal
ul
Number of animals
Step Two: Enter the in vivo formulation
% DMSO
%
% Tween 80
% ddH2O
Calculate Reset

TargetMolCalculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculation
Molecular Weight Calculator
=
X
X

Molarity Calculator allows you to calculate the

  • Mass of a compound required to prepare a solution of known volume and concentration
  • Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Concentration of a solution resulting from a known mass of compound in a specific volume
See Example

An example of a molarity calculation using the molarity calculator
What is the mass of compound required to make a 10 mM stock solution in 10 ml of water given that the molecular weight of the compound is 197.13 g/mol?
Enter 197.13 into the Molecular Weight (MW) box
Enter 10 into the Concentration box and select the correct unit (millimolar)
Enter 10 into the Volume box and select the correct unit (milliliter)
Press calculate
The answer of 19.713 mg appears in the Mass box

X
=
X

Calculator the dilution required to prepare a stock solution

Calculate the dilution required to prepare a stock solution
The dilution calculator is a useful tool which allows you to calculate how to dilute a stock solution of known concentration. Enter C1, C2 & V2 to calculate V1.

See Example

An example of a dilution calculation using the Tocris dilution calculator
What volume of a given 10 mM stock solution is required to make 20ml of a 50 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=50 μM, V2=20 ml and V1 is the unknown:
Enter 10 into the Concentration (start) box and select the correct unit (millimolar)
Enter 50 into the Concentration (final) box and select the correct unit (micromolar)
Enter 20 into the Volume (final) box and select the correct unit (milliliter)
Press calculate
The answer of 100 microliter (0.1 ml) appears in the Volume (start) box

=
/

Calculate the volume of solvent required to reconstitute your vial.

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial.
Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

g/mol

Enter the chemical formula of a compound to calculate its molar mass and elemental composition

Tip: Chemical formula is case sensitive: C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed n the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

bottom

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.

Keywords

Nintedanib 656247-17-5 Angiogenesis Tyrosine Kinase/Adaptors VEGFR FGFR PDGFR FLT Src BIBF 1120 Inhibitor Platelet-derived growth factor receptor Fibroblast growth factor receptor Vascular endothelial growth factor receptor Intedanib BIBF1120 inhibit BIBF-1120 inhibitor

 

TargetMol